Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.54 |
| ▸ | PDE4A | P27815 | 13/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.52 |
| ▸ | PDE1A | P54750 | 1/20 | 0.52 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.52 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9287682 | 0.99 | ADORA2A (0.56) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3990425 | 0.81 | PDE4A (0.57) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10420653 | 0.77 | PDE4A (0.49) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6251096 | 0.75 | PDE4A (0.64) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21381252 | 0.74 | ADORA2A (0.82) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28973355 | 0.74 | LMNA (0.62) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19953694 | 0.73 | LMNA (0.66) | ADORA2BHSD17B10 | |
| SCHEMBL27483073 | 0.72 | KMT2A (0.48) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11471017 | 0.72 | PDE4A (0.69) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7162120 | 0.71 | ADORA2A (0.47) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001479-A2 | CO-ADMINISTRATION OF ADENOSINE A1 RECEPTOR ANTAGONISTS AND ANTICONVULSANTS | Novacardia, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007117549-A2 | CO-ADMINISTRATION OF ADENOSINE A1 RECEPTOR ANTAGONISTS AND ANTICONVULSANTS | NOVACARDIA, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| EP-1755594-A1 | COMBINATION THERAPY COMPRISING AN ADENOSINE A1 RECEPTOR ANTAGONIST AND AN ALDOSTERONE INHIBITOR | Novacardia, Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105083-A1 | COMBINATION THERAPY COMPRISING AN ADENOSINE A1 RECEPTOR ANTAGONIST AND AN ALDOSTERONE INHIBITOR | NOVACARDIA, INC. (US) | 2005-11-10 | — | — | WO | claimed |
| EP-2035009-A1 | PROLONGED IMPROVEMENT OF RENAL FUNCTION COMPRISING INFREQUENT ADMINISTRATION OF AN AA1RA | Novacardia, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2035092-A2 | USE OF KW-3902 FOR ACHIEVING DIURESIS IN PATIENTS WITH CONGESTIVE HEART FAILURE AND ACUTE FLUID OVERLOAD | Novacardia, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007149366-A1 | PROLONGED IMPROVEMENT OF RENAL FUNCTION COMPRISING INFREQUENT ADMINISTRATION OF AN AA1RA | NOVACARDIA, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007149283-A2 | USE OF KW-3902 FOR ACHIEVING DIURESIS IN PATIENTS WITH CONGESTIVE HEART FAILURE AND ACUTE FLUID OVERLOAD | NOVACARDIA, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1603545-A2 | METHOD OF TREATMENT OF DISEASE USING AN ADENOSINE A1 RECEPTOR ANTAGONIST | Novacardia, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004075856-A2 | ADENOSINE A1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CARDIAC AND RENAL DISEASES | NOVACARDIA, INC. (US) | 2004-09-10 | — | — | WO | disclosed |